Jiangsu Hengrui Medicine Co., Ltd.
600276
Kedudukan dalam Saham
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Harga Saham
$6.89
Modal Pasaran
$43.94B
Perubahan (1 hari)
-2.91%
Perubahan (1 tahun)
-24.78%
Negara
CN
Perdagangan Jiangsu Hengrui Medicine Co., Ltd. (600276)
Kategori
Healthcare
Hasil untuk Jiangsu Hengrui Medicine Co., Ltd. (600276)
Hasil pada Oct 2026 TTM: 0
Menurut laporan kewangan terkini daripada Jiangsu Hengrui Medicine Co., Ltd., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Jiangsu Hengrui Medicine Co., Ltd. dari 2001 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2025 | $4.49B | 17.17% |
| 2024 | $3.83B | 18.93% |
| 2023 | $3.22B | 4.52% |
| 2022 | $3.08B | -24.33% |
| 2021 | $4.08B | -4.00% |
| 2020 | $4.25B | 26.94% |
| 2019 | $3.34B | 32.08% |
| 2018 | $2.53B | 19.08% |
| 2017 | $2.13B | 33.09% |
| 2016 | $1.60B | 11.38% |
| 2015 | $1.43B | 19.24% |
| 2014 | $1.20B | 17.65% |
| 2013 | $1.02B | 17.33% |
| 2012 | $871.59M | 20.75% |
| 2011 | $721.81M | 27.25% |
| 2010 | $567.25M | 27.86% |
| 2009 | $443.66M | 26.53% |
| 2008 | $350.63M | 30.64% |
| 2007 | $268.38M | 47.29% |
| 2006 | $182.22M | 24.73% |
| 2005 | $146.10M | 5.58% |
| 2004 | $138.38M | 9.03% |
| 2003 | $126.92M | 38.95% |
| 2002 | $91.34M | 19.17% |
| 2001 | $76.65M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
